Introducing 3-times-a-week COPAXONE® 40 mg
Experience treatment on your terms with 3-times-a-week COPAXONE® 40 mg.
- Proven effectiveness1
- Demonstrated safety and tolerability profile1
- The #1 prescribed brand for relapsing MS in the US2*
- The Shared Solutions® network of personalized support
Want to find out more about NEW 3-times-a-week COPAXONE® 40 mg from a leading MS expert? CALL AN MS-CERTIFIED NURSE – 1.800.887.8100
TAKE CONTROL WITH PROVEN EFFECTIVENESS
Since the approval of COPAXONE® (glatiramer acetate injection) for relapsing‐remitting MS in 1996, many in the MS community have trusted in its proven effectiveness across 5 large clinical studies. Most recently, 3-times-a-week COPAXONE® 40 mg was studied in the largest pivotal trial ever conducted for COPAXONE®.1
3-times-a-week COPAXONE® 40 mg: Proven to reduce the number of relapses
3-times-a-week COPAXONE® 40 mg reduced the number of relapses by 34% compared to placebo (an inactive substance).
Primary study results
Relapses, also called flare-ups or attacks, can cause new symptoms to occur or make old symptoms worse.
34
Fewer relapses
compared with
placebo1
3-times-a-week COPAXONE® 40 mg: Proven to reduce the number of brain lesions1
COPAXONE® 3-times-a-week 40 mg showed a significant cumulative reduction in the underlying disease activity as measured by brain lesions on magnetic resonance imaging (MRI) at 6 and 12 months compared to placebo.
Secondary study results
T2 lesions show areas where the brain tissue has been damaged.
35
Reduction in
the total
number of new
and enlarging
T2 lesions
Secondary study results
T1-enhancing lesions, also known as Gadolinium-enhancing T1 lesions, show areas where brain tissue is currently being attacked.
45
Reduction in
the local number
of enhancing
lesions on
T1-weighted
images
Expand Study Details
Take control now. Call Shared Solutions® today at 1-800-887-8100 to find out how you can get started on 3-times-a-week COPAXONE® 40 mg.
STAY THE COURSE WITH A THERAPY YOU TRUST
3-times-a-week COPAXONE® 40 mg offers you a demonstrated safety profile.1 With 3-times-a-week COPAXONE® 40 mg, you can feel confident in your decision to stay committed to your relapsing MS therapy.
Drug Interactions
Although not fully studied, COPAXONE® has not demonstrated any significant interactions with medications commonly used in MS patients.
This includes combination use with corticosteroids (up to 28 days)
COPAXONE® has not been formally evaluated in combination with interferon beta
COPAXONE® is Pregnancy Category B
There is no evidence of risk in humans.
Animal studies have failed to demonstrate a risk to the fetus, and there are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, COPAXONE® should be used in pregnancy only if clearly needed.
If you are pregnant or planning to become pregnant, let your doctor know.
Continue reading, HERE
Call Shared Solutions® today at 1-800-887-8100 to find out how you can feel confident with 3-times-a-week COPAXONE® 40 mg.
STAY THE COURSE WITH A THERAPY THAT FITS YOUR LIFESTYLE
…….
Share our Articles with others
